CClinicalTrials.gg
Active, not recruitingNCT07696845Updated Aug 19, 2026

C-PRF With Minimally Invasive Non-Surgical Periodontal Therapy

An interventional study of Minimally Invasive Non-Surgical Treatment and Concentrated Platelet-Rich Fibrin in Periodontitis, Intrabony Periodontal Defect and Non Surgical Periodontal Treatment, sponsored by Altinbas University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Altinbas University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This randomized controlled clinical study evaluated whether concentrated platelet-rich fibrin (C-PRF) provides additional clinical and radiographic benefits when used together with minimally invasive non-surgical periodontal treatment (MINST) in patients with advanced periodontitis and intrabony periodontal defects.

Thirty systemically healthy patients with stage III-IV periodontitis were included. Each participant had at least one intrabony defect with a probing pocket depth of 6 mm or greater and a radiographic intrabony component of 3 mm or greater. Participants were randomly assigned to receive either MINST alone or MINST combined with C-PRF application.

Clinical periodontal measurements, including probing pocket depth, clinical attachment level, plaque score, bleeding on probing, and gingival recession, were recorded at baseline and at the 6-month follow-up. Standardized periapical radiographs were used to evaluate radiographic outcomes, including total defect depth, intrabony defect depth, defect angle, and linear bone fill.

Read the detailed description

Periodontitis is a chronic multifactorial inflammatory disease associated with dysbiotic dental biofilm and progressive destruction of the tooth-supporting tissues. In advanced periodontitis, vertical alveolar bone loss may result in periodontal intrabony defects. These defects are clinically important because they are commonly associated with deep periodontal pockets, clinical attachment loss, bleeding on probing, and increased risk of further periodontal breakdown if not adequately treated.

The management of periodontal intrabony defects traditionally includes non-surgical periodontal therapy as the initial treatment approach. However, in advanced cases, residual deep pockets and persistent inflammation may remain after conventional non-surgical therapy. Minimally invasive non-surgical treatment (MINST) has been proposed as a tissue-preserving approach for the management of intrabony periodontal defects. MINST aims to remove subgingival biofilm and calculus through careful instrumentation while minimizing trauma to the periodontal tissues. The technique emphasizes the preservation of the interdental papilla and marginal gingiva, limited tissue manipulation, avoidance of aggressive root planing and gingival curettage, and support of stable blood clot formation within the defect.

In this study, MINST is performed using fine periodontal instruments and thin ultrasonic tips without flap elevation. The objective of this approach is to achieve effective subgingival debridement while preserving soft tissue architecture and supporting periodontal wound healing. The minimally invasive nature of the procedure may be particularly relevant for patients with advanced periodontitis, where maintaining gingival tissue stability and reducing postoperative morbidity are important clinical goals.

Platelet-rich fibrin (PRF) is an autologous platelet concentrate obtained from the patient's own blood. PRF contains platelets, leukocytes, fibrin, and growth factors that may contribute to wound healing, angiogenesis, tissue repair, and periodontal regeneration. Concentrated platelet-rich fibrin (C-PRF) is a liquid PRF formulation prepared by collecting the cell-rich fraction from the buffy coat layer after centrifugation. Compared with liquid PRF protocols, C-PRF is designed to provide a higher concentration of platelets and leukocytes in a small volume, potentially increasing its biological activity at the application site.

Although several studies have evaluated different adjunctive biomaterials with minimally invasive periodontal therapy, evidence regarding the use of C-PRF together with MINST in advanced periodontitis remains limited. Therefore, this study is designed to evaluate whether the adjunctive application of C-PRF may provide additional clinical and radiographic benefits when combined with MINST in patients with stage III-IV periodontitis and periodontal intrabony defects.

This is a single-center, prospective, randomized controlled clinical study conducted as part of a doctoral thesis in the Department of Periodontology at Altinbas University. A total of 30 systemically healthy participants diagnosed with stage III-IV periodontitis are included. Each participant has at least one periodontal intrabony defect with a probing pocket depth of 6 mm or greater and a radiographic intrabony component of 3 mm or greater.

Participants are randomly allocated into two treatment groups. The control group receives MINST alone. The test group receives MINST followed by adjunctive C-PRF application into the periodontal pocket associated with the selected intrabony defect. For C-PRF preparation, venous blood is collected from the patient and processed according to the C-PRF protocol. The concentrated liquid fraction is then applied locally into the periodontal pocket after completion of the MINST procedure.

Clinical periodontal measurements are recorded at baseline and at the 6-month follow-up. The evaluated clinical parameters include probing pocket depth, clinical attachment level, plaque score, bleeding on probing, and gingival recession. Measurements are performed using standardized clinical methods, and site-specific values are recorded for the selected intrabony defect sites.

Radiographic assessment is performed using standardized periapical radiographs. Customized radiographic stents are used to improve reproducibility of radiographic image acquisition between baseline and follow-up. Radiographic measurements include total defect depth, intrabony defect depth, defect angle, linear bone fill, and defect fill percentage. These measurements are used to evaluate changes in the morphology and depth of the intrabony defects over the 6-month follow-up period.

Patient-reported outcome measures are also evaluated using visual analogue scale scores. These assessments are included to evaluate patient-centered outcomes such as pain, satisfaction, and aesthetic perception following treatment.

02

Conditions studied

  • Periodontitis
  • Intrabony Periodontal Defect
  • Non Surgical Periodontal Treatment

Browse trials for

Keywords

  • Minimally Invasive Non-Surgical Treatment
  • Concentrated Platelet-Rich Fibrin
  • Intrabony Defects
  • Advanced Periodontitis
03

In context

Periodontitis

1,635 studies on the registry are indexed under Periodontitis; 327 are open to participants now.

This study's enrollment of 30 is below the median of 45 across 1,191 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Altinbas University is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Individuals aged 18 to 70 years.
  • Systemically healthy individuals.
  • Individuals diagnosed with Stage III or Stage IV periodontitis.
  • Presence of at least one periodontal intrabony defect with a radiographic intrabony defect depth of ≥3 mm.
  • Presence of probing pocket depth of ≥6 mm at the selected defect site.
  • No periapical pathology associated with the selected tooth.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation.
  • Presence of systemic diseases or use of medications that may affect periodontal healing.
  • Periodontal treatment within the recent period before enrollment.
  • Smoking ≥10 cigarettes per day.
  • Presence of periapical pathology associated with the selected tooth.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    MINST Alone

    Participants in this arm received minimally invasive non-surgical periodontal treatment (MINST) alone for the selected periodontal intrabony defect. Subgingival debridement was performed using fine ultrasonic tips and mini-curettes without flap elevation, with the aim of removing biofilm and calculus while preserving soft tissue architecture and supporting periodontal wound healing.

    Procedure: Minimally Invasive Non-Surgical Treatment

  • Active comparator
    MINST With C-PRF

    Participants in this arm received minimally invasive non-surgical periodontal treatment (MINST) followed by adjunctive application of concentrated platelet-rich fibrin (C-PRF) into the periodontal pocket associated with the selected intrabony defect. C-PRF was prepared from the participant's own venous blood and applied locally after completion of the minimally invasive debridement procedure.

    Procedure: Minimally Invasive Non-Surgical Treatment · Biological: Concentrated Platelet-Rich Fibrin

Interventions

  • ProcedureMinimally Invasive Non-Surgical Treatment

    Minimally invasive non-surgical periodontal treatment was performed for the selected periodontal intrabony defect without flap elevation. Subgingival debridement was carried out using fine ultrasonic tips and mini-curettes. The procedure aimed to remove subgingival biofilm and calculus while preserving the interdental papilla, marginal gingiva, and soft tissue architecture, and supporting stable blood clot formation within the defect.

    Also known as: MINST

  • BiologicalConcentrated Platelet-Rich Fibrin

    Concentrated platelet-rich fibrin was prepared from the participant's own venous blood according to the C-PRF protocol. After centrifugation, the concentrated liquid fraction was collected from the buffy coat region and applied locally into the periodontal pocket associated with the selected intrabony defect following completion of minimally invasive non-surgical periodontal treatment.

    Also known as: C-PRF

06

What researchers measure

Primary outcomes

  1. Change in probing pocket depth (PPD)

    Change in probing pocket depth (PPD) at the selected intrabony defect site from baseline to 6 months. PPD will be measured in millimeters using a UNC-15 periodontal probe.

    Time frame: Baseline and 6 months

  2. Change in clinical attachment level (CAL)

    Change in clinical attachment level (CAL) at the selected intrabony defect site from baseline to 6 months. CAL will be measured in millimeters using a UNC-15 periodontal probe.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Change in radiographic intrabony defect depth

    Change in radiographic intrabony defect depth (IDD) from baseline to 6 months, measured on standardized periapical radiographs.

    Time frame: Baseline and 6 months

07

Study locations

1 site
  • Altınbaş University Faculty of Dentistry, Department of Periodontology
    Istanbul, Bakırkoy 34147, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because the data contain confidential clinical information and were collected under ethical approval and informed consent for the purposes of this study only.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07696845
Lead sponsor
Altinbas University
Responsible party
Yusuf Cem Yavuz (Principal Investigator, Altinbas University) — Principal investigator
First posted
Jul 10, 2026
Start date
Aug 2, 2026
Primary completion
Feb 9, 2027 (estimated)
Completion
Feb 9, 2027 (estimated)
Last update
Aug 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion